Shares soared after a bullish report from investment bank Morgan Stanley, but is it time to buy?
Pharmaceutical spin-off AbbVie recently received a big upgrade from Wall Street bank Morgan Stanley, sending shares up 6% last week. In this video, health-care analyst David Williamson breaks down what investors need to know about this bullish report, and why they might want to show caution before buying AbbVie stock.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.